References
- Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol 2006;85:263–267.
- Jimenez-Zepeda VH, Dominguez-Martinez VJ. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. Int J Hematol 2009;89:259–268.
- Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120:1060–1066.
- Musto P, Pagano L, Petrucci MT, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2012;82:141–149.
- Gozzetti A, Musto P, Defina M, et al. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol 2012;157:497–498.
- Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679–686.
- National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology Criteria for Adverse Events. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf (Accessed July 16 2011).
- Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27:780–791.
- Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology? Eur J Haematol 2011;87:20–27.
- Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008;32:1637–1638.
- Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109:2285–2290.
- Vij R, Wang M, Kaufman JL, et al. An open-label, single- arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012;119:5661–5670.
- Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12:310–318.
- Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2012;118:2970–2975.